Imdusiran - Arbutus Biopharma
Alternative Names: AB-729; ARB 270729Latest Information Update: 25 Nov 2024
Price :
$50 *
At a glance
- Originator Arbutus Biopharma
- Developer Antios Therapeutics; Arbutus Biopharma; Assembly Biosciences
- Class Amides; Amino sugars; Antivirals; Drug conjugates; Small interfering RNA
- Mechanism of Action Hepatitis B surface antigen expression inhibitors; Hepatitis B virus replication inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Hepatitis B
Highest Development Phases
- Phase II Hepatitis B; Hepatitis D
Most Recent Events
- 15 Nov 2024 Updated efficacy and adverse events data from a phase IIa IM-PROVE I trial for Hepatitis B released by Arbutus Biopharma
- 15 Nov 2024 Updated efficacy, adverse events and immunogenicity data from the phase-IIa IM-PROVE II trial in Hepatitis B released by Arbutus Biopharma
- 15 Oct 2024 Efficacy data from the phase II IM-PROVE I trial in Hepatitis B released by Arbutus Biopharma